MPLT
HEALTHCAREMapLight Therapeutics, Inc. Common Stock
What's Moving MPLT Today?
No stock-specific AI insight has been generated for MPLT yet. Check back soon — insights are generated from recent news analysis.
Market Briefings featuring MPLT
52-Week Range
$13.42
Fundamentals
Trading
MPLT News
25 articles- Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of "Buy" from AnalystsMarketBeat·Jul 30, 2026
- MapLight CEO on what investors missed in the biotech’s schizophrenia dataBiopharmadive·Jul 29, 2026
- MapLight Therapeutics stock crashes on Phase II schizophrenia dataClinicaltrialsarena·Jul 28, 2026
- MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily DoseStocktwits·Jul 27, 2026
- Top Midday DeclinersYahoo Finance·Jul 27, 2026
- Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary EndpointMarketbeat·Jul 27, 2026
- MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data (MPLT:NASDAQ)Seeking Alpha·Jul 27, 2026
- MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in SchizophreniaThe Manila Times·Jul 27, 2026
- Is MapLight Therapeutics (MPLT) Fully Valued As Its Shares Hold Near $36.56?Yahoo Finance·Jul 26, 2026
- Maplight Therapeutics (NASDAQ:MPLT) Upgraded by BMO Capital Markets to Strong-Buy RatingMarketBeat·Jul 22, 2026
- Sector Update: Healthcare Stocks Rise Late AfternoonYahoo Finance·Jul 21, 2026
- Shopify downgraded, Five Below upgraded: Wall Street's top analyst callsYahoo Finance·Jul 21, 2026
- Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?Yahoo Finance·Jun 30, 2026
- MapLight Therapeutics Announces Changes to Board of DirectorsYahoo Finance·Jun 24, 2026
- MapLight’s autism drug trial misses primary endpoint By Investing.comInvesting.com Canada·Jun 22, 2026
- MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum DisorderYahoo Finance·Jun 22, 2026
- Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug StumblesMotley Fool·Jun 8, 2026
- Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 MillionMotley Fool·May 31, 2026
- MPLT Options Volatility — NASDAQ:MPLTTradingView·May 31, 2026
- Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could MeanMotley Fool·May 30, 2026
- MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold?Motley Fool·May 15, 2026
- MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 14, 2026
- MapLight Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·May 8, 2026
- This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of AprilMotley Fool·May 4, 2026
- MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline ResultsYahoo Finance·May 1, 2026
All 25 articles loaded
Price Data
52-Week Range
$13.42
Fundamentals
Trading
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. is a pioneering biotechnology firm focused on creating innovative therapies for complex neurological and psychiatric disorders. Leveraging its proprietary platform, the company strategically targets intricate biological pathways to develop transformative treatment solutions that aim to improve patient outcomes significantly. With a strong commitment to scientific excellence and an advancing clinical pipeline, MapLight is well-positioned to address critical unmet medical needs, positioning itself as a potential frontrunner in the rapidly evolving neurotherapeutics market.
Company Details
Analyst Rating
Insider Activity
Catalyst4, Inc.
$1.5M
Catalyst4, Inc.
$38K
Catalyst4, Inc.
$13.0M
Catalyst4, Inc.
$761K
Cox Troy
$149K
GILLIS JONATHAN
CAO and Interim CFO
$638K
GILLIS JONATHAN
CAO and Interim CFO
$174K
Kreitzer Anatol
Chief Discovery Officer
$274K